Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current drug metabolism

• Publication date

  2009-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138920009787522124PMID 19275548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis

  2008cited by this paper
• Update: vildagliptin for the treatment of Type 2 diabetes

  2008cited by this paper
• The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

  2008cited by this paper
• C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.

  2008cited by this paper
• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

  2008cited by this paper
• The GLP-1 concept in the treatment of type 2 diabetes--still standing at the gate of dawn?

  2008cited by this paper
• Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

  2008cited by this paper
• Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

  2008cited by this paper
• Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.

  2008cited by this paper
• Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.

  2008cited by this paper
• Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

  2008cited by this paper
• Dorothy Hodgkin Lecture 2008 Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity–diabetes?

  2008cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

  2007cited by this paper
• Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.

  2007cited by this paper
• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• Dipeptidyl Peptidase-IV Inhibitors: An Evolving Treatment for Type 2 Diabetes from the Incretin Concept

  2007cited by this paper
• A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice

  2007cited by this paper
• Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.

  2007cited by this paper
• A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice

  2007cited by this paper
• Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.

  2007cited by this paper
• Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

  2007cited by this paper
• Small-molecule agonists for the glucagon-like peptide 1 receptor

  2007cited by this paper
• Incretin hormone mimetics and analogues in diabetes therapeutics.

  2007cited by this paper
• Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007cited by this paper
• Sitagliptin - Enhancing incretin action

  2007cited by this paper
• Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  2007cited by this paper
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007cited by this paper
• Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets

  2007cited by this paper
• Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

  2006cited by this paper
• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

  2006cited by this paper
• Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor Antagonist*

  2006cited by this paper
• Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes

  2006cited by this paper
• Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

  2006cited by this paper
• Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic β-Cell Mass

  2006cited by this paper
• Exenatide: A Novel Incretin Mimetic Agent for Treating Type 2 Diabetes Mellitus

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

  2006cited by this paper
• Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice

  2006cited by this paper
• Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

  2006cited by this paper
• Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

  2006cited by this paper
• Review: Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes:

  2006cited by this paper
• Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.

  2006cited by this paper
• Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes

  2006cited by this paper
• Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice

  2006cited by this paper
• A Novel, Long-Acting Agonist of Glucose-Dependent Insulinotropic Polypeptide Suitable for Once-Daily Administration in Type 2 Diabetes

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.

  2005cited by this paper
• Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression*

  2005cited by this paper
• Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

  2005cited by this paper
• Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)

  2005cited by this paper
• Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

  2005cited by this paper
• Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide.

  2005cited by this paper
• Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

  2005cited by this paper
• The physiological role of GLP-1 in human: incretin, ileal brake or more?

  2005cited by this paper
• Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

  2005cited by this paper
• Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes

  2004cited by this paper
• Circulation and Degradation of GIP and GLP-1

  2004cited by this paper
• Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

  2004cited by this paper
• Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

  2004cited by this paper
• Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

  2004cited by this paper
• Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients.

  2004cited by this paper
• A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog.

  2004cited by this paper
• Therapeutic strategies based on glucagon-like peptide 1.

  2004cited by this paper
• One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

  2004cited by this paper
• The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

  2004cited by this paper
• The Development of Beta-cell Mass: Recent Progress and Potential Role of GLP-1

  2004cited by this paper
• Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.

  2003cited by this paper
• Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

  2003cited by this paper
• Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.

  2003cited by this paper
• Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects.

  2003cited by this paper
• Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

  2003cited by this paper
• Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats

  2003cited by this paper
• CJC-1131. ConjuChem.

  2003cited by this paper
• The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

  2003cited by this paper
• Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

  2002cited by this paper
• Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

  2002cited by this paper
• Inhibition of gastric inhibitory polypeptide signaling prevents obesity

  2002cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

  2002cited by this paper
• Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.

  2002cited by this paper
• Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells.

  2002cited by this paper
• Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.

  2002cited by this paper
• The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

  2002cited by this paper
• Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice

  2000cited by this paper
• Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants.

  2000cited by this paper

• Organic clay-based fast dissolving microneedles for efficient transdermal delivery of therapeutic proteins

  2024cites this paper
• Insulinotropic and glucose-lowering peptides from phylogenetically ancient fish with potential for therapy of type 2 diabetes

  2019cites this paper
• Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice

  2019cites this paper
• EFFECTS OF DIABETES

  2019cites this paper
• Suppressive effect of ascophyllan HS on postprandial blood sugar level through the inhibition of α-glucosidase and stimulation of glucagon-like peptide-1 (GLP-1) secretion.

  2019cites this paper
• Characterisation and antidiabetic utility of a novel hybrid peptide, exendin‐4/gastrin/xenin‐8‐Gln

  2018cites this paper
• Peptides and Diabetes 2 PEPTIDES FOR DIABETES RESEARCH

  2017cites this paper
• Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.

  2017cites this paper
• Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders.

  2016cites this paper
• STUDY ON THE EFFECT OF AROMATIC COMPOUNDS ON THE ACTIVITY OF BOVINE SERUM ALPHA-AMYLASE: A SEARCH FOR POTENTIALLY ACTIVE COMPOUNDS IN CONTROLLING BLOOD SUGAR LEVEL

  2016cites this paper
• Potential therapeutic applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents.

  2014cites this paper
• Effects of chronic exposure of clonal β‐cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP‐1

  2014cites this paper
• Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes

  2014cites this paper
• Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress

  2014cites this paper
• Education-Family Physician Corner Therapeutic Choices within Diabetes

  2013cites this paper
• A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice*

  2013cites this paper
• Therapeutic Choices within Diabetes

  2013cites this paper
• Glucose: Metabolism and Maintenance of Blood Glucose Level

  2013cites this paper
• Insulinotropic Actions of the Frog Skin Host‐Defense Peptide Alyteserin‐2a: A Structure–Activity Study

  2013cites this paper
• Caerulein precursor fragment (CPF) peptides from the skin secretions of Xenopus laevis and Silurana epitropicalis are potent insulin-releasing agents.

  2013cites this paper
• Incretins: new targets for the prevention of diabetes and obesity

  2013cites this paper
• Frog skin peptides (tigerinin-1R, magainin-AM1, -AM2, CPF-AM1, and PGla-AM1) stimulate secretion of glucagon-like peptide 1 (GLP-1) by GLUTag cells.

  2013cites this paper
• Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry

  2012cites this paper
• Effect of dietary coconut kernel protein on the liver and pancreas of alloxan-induced diabetic rats: comparison with l-arginine and glibenclamide

  2012cites this paper
• Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes

  2012cites this paper
• Hematopoietic, CNS and skeletal muscle stem cells as drug targets: opportunities, progress and challenges.

  2012cites this paper
• the effects of GLP-1 on SIRT1 and on the related metabolic pathways in vascular endothelial cells: potential effects on vascular injury in diabetic patients

  2012cites this paper
• Renal glucose reabsorption inhibitors to treat diabetes.

  2011cites this paper
• Peptidomic analysis of skin secretions from the bullfrog Lithobates catesbeianus (Ranidae) identifies multiple peptides with potent insulin-releasing activity.

  2011cites this paper
• In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1)

  2011influential citation
• Caerulein-and xenopsin-related peptides with insulin-releasing activities from skin secretions of the clawed frogs, Xenopus borealis and Xenopus amieti (Pipidae).

  2011cites this paper
• Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.

  2011cites this paper
• Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R-/- mice

  2011cites this paper
• The challenge of managing coexistent type 2 diabetes and obesity

  2011cites this paper
• Management of type 2 diabetes: new and future developments in treatment.

  2011cites this paper
• Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

  2010cites this paper
• Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.

  2010cites this paper
• Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistance

  2010cites this paper
• Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.

  2010cites this paper
• Chapter 29. Oral Antidiabetic Agents

  2010cites this paper
• Chapter 60. Future Drug Treatments for Type 2 Diabetes

  2010cites this paper
• Treatment of diabetes with glucagon-like peptide-1 gene therapy

  2010cites this paper
• Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.

  2010cites this paper
• Future Drug Treatments for Type 2 Diabetes

  2010cites this paper
• Fixed‐dose single tablet antidiabetic combinations

  2009cites this paper
• Review: Bariatric surgery: to treat diabesity

  2009cites this paper
• Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?

  2009influential citation
• mellitus by drugs modulating the incretin system

  2009cites this paper
• New therapies for diabesity

  2009cites this paper
• Current and emerging pharmacotherapy for managing diabesity

  year unknowninfluential citation